ONCT — Oncternal Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $1.56m
- -$13.02m
- $0.79m
Annual income statement for Oncternal Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2.42 | 3.38 | 4.32 | 1.49 | 0.785 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 35.5 | 20.9 | 35.7 | 46.4 | 42.5 |
| Operating Profit | -33.1 | -17.5 | -31.4 | -44.9 | -41.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -34.2 | -17.2 | -31.3 | -44.2 | -39.5 |
| Net Income After Taxes | -34.2 | -17.2 | -31.3 | -44.2 | -39.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -34.2 | -17.2 | -31.3 | -44.2 | -39.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -34.2 | -17.2 | -31.3 | -44.2 | -39.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -66.2 | -17 | -12.7 | -16.8 | -13.4 |